VIDEO: KEYNOTE 335 needs more data, but could provide ‘huge benefit’
Click Here to Manage Email Alerts
In this video, Sara M. Tolaney, MD, MPH, breast medical oncologist at Dana Farber Cancer Institute, shared her thoughts on data from the KEYNOTE 355 study presented during the ASCO20 Virtual Scientific Program.
In the KEYNOTE 335 phase 3 trial, researchers investigated the benefits of adding pembrolizumab to chemotherapy for patients with first line metastatic triple-negative disease. They found pembrolizumab combined with chemotherapy yielded statistically significant and meaningful improvement in progression-free survival vs. chemotherapy alone as a first-line treatment for metastatic triple-negative breast cancer with PD-L1 CPS 10 or higher tumors.
According to Tolaney, the study was unique because it permitted choice of chemotherapy backbone, allowing patients to receive either paclitaxel, or NAB Paclitaxel or carboplatin with gemcitabine, and then investigators randomly assigned patients to chemotherapy with or without pembrolizumab.
“Many of us anticipate there will be a survival benefit seen, and we just need to wait for more mature data. This will be a huge benefit, because we've been struggling with choice of chemotherapy backbone and patients who recur soon after regiment taxing, and to have that option of giving a platinum-based treatment will make a big difference,” she said.
Collapse
Click Here to Manage Email Alerts